Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) Price & Performance

Cassava Sciences IncTrade
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)Trade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Haleon plc American Depositary Shares (Each representing two Ordinary Shares) — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.28 (market cap $39.95B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is far larger — about 1014× Cassava Sciences Inc's market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays a 2.2% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 0 Days on average.

FLNAHLN
Market Cap
$39.40M$39.95B
Volume
759,01818,243,581
Sector
HealthHealth
52-Week High
$4.64$11.27
52-Week Low
$0.68$8.70
Typical Hold Time
37 Days0 Days
Enterprise Value
-$43.28M$49.77B
Dividend Yield
—2.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.

Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLNA
73% Buy27% Sell
Avg holding period · 37 Days
HLN
100% Buy0% Sell
Avg holding period · 0 Days

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA →

About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.

Read more on HLN →